Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Investment Securities: 2021-2024

Historic Gains from Investment Securities for Taysha Gene Therapies (TSHA) over the last 4 years, with Dec 2024 value amounting to $3.7 million.

  • Taysha Gene Therapies' Gains from Investment Securities rose 185.24% to $699,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$327,000, marking a year-over-year decrease of 100.96%. This contributed to the annual value of $3.7 million for FY2024, which is 48.33% down from last year.
  • Taysha Gene Therapies' Gains from Investment Securities amounted to $3.7 million in FY2024, which was down 48.33% from $7.2 million recorded in FY2023.
  • Taysha Gene Therapies' Gains from Investment Securities' 5-year high stood at $26.2 million during FY2021, with a 5-year trough of $1.1 million in FY2022.
  • In the last 3 years, Taysha Gene Therapies' Gains from Investment Securities had a median value of $3.7 million in 2024 and averaged $4.0 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 95.93% in 2022, then soared by 570.87% in 2023.
  • Yearly analysis of 4 years shows Taysha Gene Therapies' Gains from Investment Securities stood at $26.2 million in 2021, then slumped by 95.93% to $1.1 million in 2022, then skyrocketed by 570.87% to $7.2 million in 2023, then tumbled by 48.33% to $3.7 million in 2024.